Negative symptoms in schizophrenia: A comprehensive review of electrophysiological investigations

Clinical Schizophrenia and Related Psychoses

Volumn 8, Issue 1, 2014, Pages

  Boutros, Nash N ^a   Mucci, Armida ^b   Diwadkar, Vaibhav ^c   Tandon, Rajiv ^d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Deficit syndrome; Electroencephalography (EEG); Evoked potentials (EPs); Negative symptoms; Polysomnography (PSG); Schizophrenia

Indexed keywords

ALPHA RHYTHM; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGICAL PROCEDURES; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; HUMAN; NEGATIVE SYNDROME; POLYSOMNOGRAPHY; PREVALENCE; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SLOW WAVE SLEEP; WAKEFULNESS; WAVEFORM; BRAIN; DRUG EFFECTS; ELECTROPHYSIOLOGY; EVOKED RESPONSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

NEUROLEPTIC AGENT;

ANTIPSYCHOTIC AGENTS; BRAIN; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGICAL PHENOMENA; EVOKED POTENTIALS; HUMANS; POLYSOMNOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84902176100     PISSN: 19351232     EISSN: 19412010     Source Type: Journal    
DOI: 10.3371/CSRP.BOMU.012513     Document Type: Review

References (85)

1. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007;115(1):4-11.
2. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson MD, Eiser A, et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 2000;45(3):191-201.
3. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007;33(4):1013-1022.
4. Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry 2005;162(1):124-129.
5. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67 Suppl 9:3-8; discussion 36-42.
6. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26(1):119-136.
7. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004;65(3):361-372.
8. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32(2):214-219.
9. Marder SR. Drug initiatives to improve cognitive function. J Clin Psychiatry 2006;67 Suppl 9:31-35; discussion 36-42.
10. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72(1):5-9.
11. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-1602.
12. Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry 2008;64(1):4-10.
13. Galderisi S, Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry 2009;24(8):493-500.
14. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30(2):119-123.
15. Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry 2008;7(3):143-147.
16. Boutros NN, Gjini K, Arfken CL. Advances in electrophysiology in the diagnosis of behavioral disorders. Expert Opin Med Diagn 2011;5(5):441-452.
17. Boutros NN, Arfken C, Galderisi S, Warrick J, Pratt G, Iacono W. The status of EEG abnormality as a diagnostic test for schizophrenia. Schizophr Res 2008;99(1-3):225-237.
18. Force RB, Venables NC, Sponheim SR. An auditory processing abnormality specific to liability for schizophrenia. Schizophr Res 2008;103(1-3):298-310.
19. Venables NC, Bernat EM, Sponheim SR. Genetic and disorder-specific aspects of resting state EEG abnormalities in schizophrenia. Schizophr Bull 2009;35(4):826-839.
20. Erwin RJ, Mawhinney-Hee M, Gur RC, Gur RE. Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry 1991;30(5):430-442.
21. Rosburg T, Boutros NN, Ford JM. Reduced auditory evoked potential component N100 in schizophrenia - a critical review. Psychiatry Res 2008;161(3):259-274.
22. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982;17(6):639-654.
23. Boutros NN, Zouridakis G, Overall J. Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 1991;22(1):40-45.
24. Freedman R, Waldo M, Bickford-Wimer P, Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schizophr Res 1991;4(2):233-243.
25. Boutros NN, Brockhaus-Dumke A, Gjini K, Vedeniapin A, Elfakhani M, Burroughs S, et al. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr Res 2009;113(2-3):339-346.
26. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008;158(2):226-247.
27. Ahveninen J, Jääskeläinen IP, Osipova D, Huttunen MO, Ilmoniemi RJ, Kaprio J, et al. Inherited auditory-cortical dysfunction in twin pairs discordant for schizophrenia. Biol Psychiatry 2006;60(6):612-620.
28. Adler LE, Waldo MC, Tatcher A, Cawthra E, Baker N, Freedman R. Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr Res 1990;3(2):131-138.
29. Boutros NN, Korzyukov O, Jansen B, Feingold A, Bell M. Sensory-gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 2004;126(3):203-215.
30. Ringel TM, Heidrich A, Jacob CP, Pfuhlmann B, Stoeber G, Fallgatter AJ. Sensory gating deficit in a subtype of chronic schizophrenic patients. Psychiatry Res 2004;125(3):237-245.
31. Louchart-de la Chapelle S, Levillain D, Menard JF, Van der Elst A, Allio G, Haouzir S, et al. P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia. Psychiatry Res 2005;136(1):27-34.
32. Arnfred S. Exploration of auditory P50 gating in schizophrenia by way of difference wave. Behav Brain Funct 2006;2:6
33. Santos JL, Sánchez-Morla EM, Aparicio A, García- Jiménez MA, Villanueva C, Martínez-Vizcaíno V, et al. P50 gating in deficit and nondeficit schizophrenia. Schizophr Res 2010;119(1-3):183-190.
34. Galderisi S, Mucci A, Volpe U, Boutros N. Evidence-based medicine and electrophysiology in schizophrenia. Clin EEG Neurosci 2009;40(2):62-77.
35. Näätänen R, Kähkönen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol 2009;12(1):125-135.
36. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007;33(1):69-94.
37. Blackwood DH, St Clair DM, Muir WJ, Duffy JC. Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch Gen Psychiatry 1991;48(10):899-909.
38. Bramon E, McDonald C, Croft RJ, Landau S, Filbey F, Gruzelier JH, et al. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Neuroimage 2005;27(4):960-968.
39. Bestelmeyer PE, Phillips LH, Crombie C, Benson P, St Clair D. The P300 as a possible endophenotype for schizophrenia and bipolar disorder: Evidence from twin and patient studies. Psychiatry Res 2009;169(3):212-219.
40. Pfefferbaum A, Ford JM, White PM, Roth WT. P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Arch Gen Psychiatry 1989;46(11):1035-1044.
41. Eikmeier G, Lodemann E, Zerbin D, Gastpar M. P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: a preliminary report. Biol Psychiatry 1992;31(10):1065-1069.
42. Liu Z, Tam WC, Xue Z, Yao S, Wu D. Positive and negative symptom profile schizophrenia and abnormalities in the P300 component of the event-related potential: a longitudinal controlled study. Psychiatry Res 2004;132(2):131-139.
43. Strik WK, Dierks T, Maurer K. Amplitudes of auditory P300 in remitted and residual schizophrenics: correlations with clinical features. Neuropsychobiology 1993;27(1):54-60.
44. McCarley RW, Shenton ME, O'Donnell BF, Faux SF, Kikinis R, Nestor PG, et al. Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Arch Gen Psychiatry 1993;50(3):190-197.
45. Kawasaki Y, Maeda Y, Higashima M, Nagasawa T, Koshino Y, Suzuki M, et al. Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia. Schizophr Res 1997;26(2-3):107-115.
46. Ford JM, Mathalon DH, Marsh L, Faustman WO, Harris D, Hoff AL, et al. P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia. Biol Psychiatry 1999;46(1):94-101.
47. Frodl-Bauch T, Gallinat J, Meisenzahl EM, Möller HJ, Hegerl U. P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol Psychiatry 1999;45(1):116-126.
48. Frodl T, Meisenzahl EM, Müller D, Holder J, Juckel G, Möller HJ, et al. P300 subcomponents and clinical symptoms in schizophrenia. Int J Psychophysiol 2002;43(3):237-246.
49. Meisenzahl EM, Frodl T, Müller D, Schmitt G, Gallinat J, Zetzsche T, et al. Superior temporal gyrus and P300 in schizophrenia: a combined ERP/structural magnetic resonance imaging investigation. J Psychiatr Res 2004;38(2):153-162.
50. Turetsky B, Colbath EA, Gur RE. P300 subcomponents abnormalities in schizophrenia. I. Physiological evidence for gender and subtype specific regional pathology. Biol Psychiatry 1998;43(2):84-96.
51. Mucci A, Galderisi S, Kirkpatrick B, Bucci P, Volpe U, Merlotti E, et al. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophr Res 2007;92(1-3):252-261.
52. Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 2003;40(5):684-701.
53. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009;110(1-3):1-23.
54. Pinault D. Dysfunctional thalamus-related networks in schizophrenia. Schizophr Bull 2011;37(2):238-243.
55. Sekimoto M, Kato M, Watanabe T, Kajimura N, Takahashi K. Cortical regional differences of delta waves during all-night sleep in schizophrenia. Schizophr Res 2011;126(1-3):284-290.
56. Steriade M, Llinás RR. The functional states of the thalamus and the associated neuronal interplay. Physiol Rev 1988;68(3):649-742.
57. Siegel JM. Sleep mechanisms and phylogeny. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis (MI): Elsevier; 2011. p. 76-91.
58. Krause M, Hofffmann WE, Hajos M. Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats. Biol Psychiatry 2003;53(3):244-253.
59. Kirkpatrick B, Buchanan RW. The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 1990;178(9):545-555.
60. Clarke DL, Boutros NN, Mendez MF. The brain and behavior: an introduction to behavioral neuroanatomy. 3rd ed. New York: Cambridge University Press; 2010. p. 156-166.
61. Staines WR, Black SE, Graham SJ, McIlroy WE. Somatosensory gating and recovery from stroke involving the thalamus. Stroke 2002;33(11):2642-2651.
62. Byne W, Hazlett EA, Buchsbaum MS, Kemether E. The thalamus and schizophrenia: current status of research. Acta Neuropathol 2009;117(4):347-368.
63. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 2007;33(5):1201-1212.
64. Williamson PC, Kutcher SP, Cooper PW, Snow WG, Szalai JP, Kaye H, et al. Psychological, topographic EEG, and CT scan correlates of frontal lobe function in schizophrenia. Psychiatry Res 1989;29(2):137-149.
65. Kessler C, Kling A. EEG power variation in schizophrenic subgroups: effects of emotionally salient stimuli. Biol Psychiatry 1991;30(4):335-348.
66. Merrin EL, Floyd TC. Negative symptoms and EEG alpha in schizophrenia: a replication. Schizophr Res 1996;19(2-3):151-161.
67. Sponheim SR, Iacono WG, Clementz BA, Beiser M. Season of birth and electroencephalogram power abnormalities in schizophrenia. Biol Psychiatry 1997;41(10):1020-1027.
68. Sponheim SR, Clementz BA, Iacono WG, Beiser M. Clinical and biological concomitants of resting state EEG power abnormalities in schizophrenia. Biol Psychiatry 2000;48(11):1088-1097.
69. Knott VJ. Quantitative EEG methods and measures in human psychopharmacological research. Hum Psychopharmacol 2000;15(7):479-498.
70. Winterer G, Ziller M, Dorn H, Frick K, Mulert C, Wuebben Y, et al. Frontal dysfunction in schizophrenia - a new electrophysiological classifier for research and clinical applications. Eur Arch Psychiatry Clin Neurosci 2000;250(4):207-214.
71. Strelets VB, Novototsky-Vlasov VY, Golikova JV. Cortical connectivity in high frequency beta-rhythm in schizophrenics with positive and negative symptoms. Int J Psychophysiol 2002;44(2):101-115.
72. Fehr T, Kissler J, Wienbruch C, Moratti S, Elbert T, Watzl H, et al. Source distribution of neuromagnetic slow-wave activity in schizophrenic patients - effects of activation. Schizophr Res 2003;63(1-2):63-71.
73. Manchanda R, Norman R, Malla A, Harricharan R, Northcott S. EEG abnormalities and 3-year outcome in first episode psychosis. Acta Psychiatr Scand 2008;117(4):277-282.
74. Boutros NN, Zouridakis G, Rustin T, Peabody C, Warner D. The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res 1993;47(3):243-254.
75. Baldeweg AK, Klugman A, Gruzelier JH, Hirsch SR. Impairment in frontal but not temporal components of mismatch negativity in schizophrenia. Int J Psychophysiol 2002;43(2):111-122.
76. Thoma RJ, Hanlon FM, Moses SN, Ricker D, Huang M, Edgar C, et al. M50 sensory gating predicts negative symptoms in schizophrenia. Schizophr Res 2005;73(2-3):311-318
77. Toyomaki A, Kusumi I, Matsuyama T, Kako Y, Ito K, Koyama T. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):95-99.
78. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, et al. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res 2010;119(1-3):175-182.
79. Ganguli R, Reynolds CF 3rd, Kupfer DJ. Electroencephalographic sleep in young, never-medicated schizophrenics. A comparison with delusional and nondelusional depressives and with healthy controls. Arch Gen Psychiatry 1987;44(1):36-44.
80. van Kammen DP, van Kammen WB, Peters J, Goetz K, Neylan T. Decreased slow-wave sleep and enlarged lateral ventricles in schizophrenia. Neuropsychopharmacology 1988;1(4):265-271.
81. Neylan TC, van Kammen DP, Kelley ME, Peters JL. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients. Arch Gen Psychiatry 1992;49(8):643-649.
82. Keshavan MS, Miewald J, Haas G, Sweeney J, Ganguli R, Reynolds CF. Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders. J Psychiatr Res 1995;29(4):303-314.
83. Kato M, Kajimura N, Okuma T, Sekimoto M, Watanabe T, Yamadera H, et al. Association between delta waves during sleep and negative symptoms in schizophrenia. Pharmaco-eeg studies by using structurally different hypnotics. Neuropsychobiology 1999;39(3):165-172.
84. Müller MJ, Rossbach W, Mann K, Röschke J, Müller- Siecheneder F, Blümler M, et al. Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry 2004;37(4):157-162.
85. Poulin J, Stip E, Godbout R. REM sleep EEG spectral analysis in patients with first-episode schizophrenia. J Psychiatr Res 2008;42(13):1086-1093.